Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia
Tóm tắt
Aminoglycosides aerosolization might achieve better diffusion into the alveolar compartment than intravenous use. The objective of this multicenter study was to evaluate aerosol-delivered amikacin penetration into the alveolar epithelial lining fluid (ELF) using a new vibrating mesh nebulizer (Pulmonary Drug Delivery System (PDDS), Nektar Therapeutics), which delivers high doses to the lungs. Nebulized amikacin (400 mg bid) was delivered to the lungs of 28 mechanically ventilated patients with Gram-negative VAP for 7-14 days, adjunctive to intravenous therapy. On treatment day 3, 30 minutes after completing aerosol delivery, all the patients underwent bronchoalveolar lavage in the infection-involved area and the ELF amikacin concentration was determined. The same day, urine and serum amikacin concentrations were determined at different time points. Median (range) ELF amikacin and maximum serum amikacin concentrations were 976.1 (135.7-16127.6) and 0.9 (0.62-1.73) μg/mL, respectively. The median total amount of amikacin excreted in urine during the first and second 12-hour collection on day 3 were 19 (12.21-28) and 21.2 (14.1-29.98) μg, respectively. During the study period, daily through amikacin measurements were below the level of nephrotoxicity. Sixty-four unexpected adverse events were reported, among which 2 were deemed possibly due to nebulized amikacin: one episode of worsening renal failure, and one episode of bronchospasm. PDDS delivery of aerosolized amikacin achieved very high aminoglycoside concentrations in ELF from radiography-controlled infection-involved zones, while maintaining safe serum amikacin concentrations. The ELF concentrations always exceeded the amikacin minimum inhibitory concentrations for Gram-negative microorganisms usually responsible for these pneumonias. The clinical impact of amikacin delivery with this system remains to be determined. ClinicalTrials.gov Identifier: NCT01021436.
Tài liệu tham khảo
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 2005, 171: 388-416. 10.1164/rccm.200405-644ST
Valcke YJ, Vogelaers DP, Colardyn FA, Pauwels RA: Penetration of netilmicin in the lower respiratory tract after once-daily dosing. Chest 1992, 101: 1028-1032. 10.1378/chest.101.4.1028
Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G: Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005, 128: 545-552. 10.1378/chest.128.2.545
Boselli E, Breilh D, Djabarouti S, Guillaume C, Rimmele T, Gordien JB, Xuereb F, Saux MC, Allaouchiche B: Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med 2007, 33: 1519-1523. 10.1007/s00134-007-0688-x
Goldstein I, Wallet F, Robert J, Becquemin MH, Marquette CH, Rouby JJ: Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002, 165: 171-175.
Klepser ME: Role of nebulized antibiotics for the treatment of respiratory infections. Curr Opin Infect Dis 2004, 17: 109-112. 10.1097/00001432-200404000-00007
Fink JB, Schmidt D: In vitro comparison of nebulizers for aerosol delivery during mechanical ventilation. Am J Respir Crit Care Med 2002, 165: A375.
Ferrari F, Liu ZH, Lu Q, Becquemin MH, Louchahi K, Aymard G, Marquette CH, Rouby JJ: Comparison of lung tissue concentrations of nebulized ceftazidime in ventilated piglets: ultrasonic versus vibrating plate nebulizers. Intensive Care Med 2008, 34: 1718-1723. 10.1007/s00134-008-1126-4
Dhand R, Sohal H: Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients. Expert Rev Med Devices 2008, 5: 9-18. 10.1586/17434440.5.1.9
Chastre J, Fagon JY: Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002, 165: 867-903.
Luyt CE, Combes A, Nieszkowska A, Reynaud C, Tonnellier M, Trouillet JL, Chastre J: Does invasive diagnosis of nosocomial pneumonia during off-hours delay treatment? Intensive Care Med 2007, 33: 734-737. 10.1007/s00134-007-0562-x
Niederman MS, Chastre J, Corkery K, Marcantonio A, Fink JB, Luyt CE, Sanchez M: Inhaled amikacin reduces IV antibiotic use in intubated mechanically ventilated patients [abstract]. Am J Respir Crit Care Med 2007, 175: A326.
Chastre J, Fagon JY, Bornet-Lecso M, Calvat S, Dombret MC, al Khani R, Basset F, Gibert C: Evaluation of bronchoscopic techniques for the diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995, 152: 231-240.
Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG: Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 1986, 60: 532-538.
Lamer C, de Beco V, Soler P, Calvat S, Fagon JY, Dombret MC, Farinotti R, Chastre J, Gibert C: Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993, 37: 281-286.
Streit JM, Jones RN, Sader HS, Fritsche TR: Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004, 24: 111-118. 10.1016/j.ijantimicag.2003.12.019
Sader HS, Jones RN: In vitro activity of amikacin tested against bacterial isolates from patients with pneumonia hospitalized in intensive care units Commissioned report. North Liberty: The JONES group/JMI Laboratories; 2004.
Goldstein I, Wallet F, Nicolas-Robin A, Ferrari F, Marquette CH, Rouby JJ: Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002, 166: 1375-1381. 10.1164/rccm.200204-363OC
Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin ME, Kergueris MF, Bugnon D, Baron D: Lung distribution and pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993, 147: 1279-1282.
Le Conte P, Potel G, Clementi E, Legras A, Villers D, Bironneau E, Cousson J, Baron D: [Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study]. Presse Med 2000, 29: 76-78.
Palmer LB, Smaldone GC, Simon SR, O'Riordan TG, Cuccia A: Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998, 26: 31-39. 10.1097/00003246-199801000-00013
Ehrmann S, Mercier E, Vecellio L, Ternant D, Paintaud G, Dequin PF: Pharmacokinetics of high-dose nebulized amikacin in mechanically ventilated healthy subjects. Intensive Care Med 2008, 34: 755-762. 10.1007/s00134-007-0935-1
Pedersen KM, Handlos VN, Heslet L, Kristensen HG: Factors influencing the in vitro deposition of tobramycin aerosol: a comparison of an ultrasonic nebulizer and a high-frequency vibrating mesh nebulizer. J Aerosol Med 2006, 19: 175-183. 10.1089/jam.2006.19.175
Luyt CE, Jacob A, Combes A, Nieszkowszka A, Fernandez C, Trouillet JL, Corkery K, Farinotti R, Chastre J: NKTR-061 (inhaled amikacin) achieves high epithelial lining fluid concentrations in Gram-negative pneumonia in intubated and mechanically ventilated patients [abstract]. Am J Respir Crit Care Med 2007, 175: A328. 10.1164/rccm.200609-1322OC
Ferrari F, Goldstein I, Nieszkowszka A, Elman M, Marquette CH, Rouby JJ: Lack of lung tissue and systemic accumulation after consecutive daily aerosols of amikacin in ventilated piglets with healthy lungs. Anesthesiology 2003, 98: 1016-1019. 10.1097/00000542-200304000-00033
Mingeot-Leclercq MP, Tulkens PM: Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother 1999, 43: 1003-1012.
Niederman MS, Sanchez M, Corkery K, Guntupalli K, Luyt C, Chastre J: Amikacin aerosol achieves high tracheal aspirate concentrations in intubated mechanically ventilated patients with Gram negative pneumonia: a pharmacokinetic study [abstract]. Am J Respir Crit Care Med 2007, 175: A326.